Anja Borgmann-Staudt

Prof. Dr. Anja Borgmann-Staudt


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2011 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
ABAnja Borgmann-Staudt
Anja Borgmann-Staudt
RRR Rendtorff
R Rendtorff
SRS Reinmuth
S Reinmuth
CHC Hohmann
C Hohmann
TKT Keil
T Keil
GSG Strauss
G Strauss

15 May 2003 in Blood
Verified
Journal Article
Closed access
PDF file
ABAnja Borgmann-Staudt
Anja Borgmann-Staudt
ASArend von Stackelberg
Arend von Stackelberg
RHReinhard Hartmann
Reinhard Hartmann
WEWolfram Ebell
Wolfram Ebell
TKThomas Klingebiel
Thomas Klingebiel
GHGünter Henze
Günter Henze
Allogeneic stem cell transplantation (SCT) is frequently considered as treatment for relapsed childhood acute lymphoblastic leukemia (ALL). For patients without a matched sibling donor, SCT from unrelated donors (UD-SCT) has been increasingly performed during the past years. However, UD-SCT–related mortality and morbidity is still considerable, and the question remains as to which patients are at such high risk of recurrence that UD-SCT is indicated and, conversely, which patients do not require transplantation for long-term disease control. A matched-pair analysis was performed among patients treated according to Acute Lymphoblastic Leukemia Relapse Berlin-Frankfurt-Münster (ALL-REZ BFM) Study Group protocols after first relapse with chemotherapy or UD-SCT. Altogether 81 pairs were identified that could be matched exactly for site of relapse and immunophenotype, and as closely as possible for duration of first remission, age, diagnosis date, and peripheral blast cell count at relapse. No significant difference in the probability of event-free survival (pEFS) between UD-SCT and chemotherapy existed regarding 28 pairs with an intermediate prognosis (0.39 ± 0.10 vs 0.49 ± 0.11,P = .105), whereas the pEFS was significantly different in the 53 pairs with a poor prognosis (0.44 ± 0.07 vs 0.00 ± 0.00, P < .001). The major reasons of treatment failure among patients who underwent UD-SCT were therapy-related death (TRD; 24/81) and relapses (20/81). In contrast, TRD rarely occurred in patients treated with chemotherapy alone (3/81), but relapse was much more common (62/81). In conclusion, UD-SCT provides better event-free survival for children with high-risk relapsed ALL. However, there is no clear advantage of UD-SCT in patients with intermediate prognosis.

1 January 2008 in European Journal of Cancer
Verified
Journal Article
Closed access
ABAnja Borgmann-Staudt
Anja Borgmann-Staudt
CZChristina Zinn
Christina Zinn
RHReinhard Hartmann
Reinhard Hartmann
RHRalf Herold
Ralf Herold
PKPeter Kaatsch
Peter Kaatsch
ASArend von Stackelberg
Arend von Stackelberg

2 October 2013 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SRSimone Reinmuth
Simone Reinmuth
CHCynthia Hohmann
Cynthia Hohmann
RRRosa Rendtorff
Rosa Rendtorff
MBMagdalena Balcerek
Magdalena Balcerek
SHSteve Holzhausen
Steve Holzhausen
ABAnja Borgmann-Staudt
Anja Borgmann-Staudt

1 August 2014 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
CPC. Pfitzer
C. Pfitzer
HOH. Orawa
H. Orawa
MBM. Balcerek
M. Balcerek
TLT. Langer
T. Langer
UDU. Dirksen
U. Dirksen
ABAnja Borgmann-Staudt
Anja Borgmann-Staudt

31 May 2010 in Klinische Padiatrie
Verified
Journal Article
Closed access
PDF file
RRR. Rendtorff
R. Rendtorff
CHC. Hohmann
C. Hohmann
SRS. Reinmuth
S. Reinmuth
AMA. Müller
A. Müller
RDR. Dittrich
R. Dittrich
ABAnja Borgmann-Staudt
Anja Borgmann-Staudt
Background: Since prevalence of and reasons for infertility were unclear in survivors of childhood cancer we conducted a two centre survey in 2006 and nationwide in 2008. In 2008/2009 we undertook a study entitled “Hormone and Sperm Analyses after Chemo- and Radiotherapy in Childhood and Adolescence”. Patients and Methods: Letters were sent to 748 former paediatric oncological patients who were at least 18 years of age at the time of the survey. Serum and sperm samples were analysed. Results: We obtained 159 blood samples (86 women, 73 men). 42 men took part in the sperm analyses. The average participants’ age at the time of the survey was 25 years. The anti-Mullerian hormone levels (AMH) in 14/86 female participants (16%) were <0.1 ng/ml. The follicular reserve of these women seemed manifestly impaired, which is consistent with suspected infertility. The AMH levels in 21/86 women (24%) were 0.1–1.0 ng/ml indicating limited follicular reserve and therefore suspected early ovarian failure. Inhibin B levels of 10 IU/L were found in 23/73 male participants (32%), which may indicate impaired spermiogenesis with increased risk of infertility. 13/42 sperm analyses (31%) revealed azoospermia. Discussion: Paediatric oncological therapy seems to have led to fertility impairment in about 1/3 of the participants. Considering this serious impairment, patients and their families should be given comprehensive counselling ahead of therapy to enable fertility-preserving measures. For persons who wish to have children after undergoing therapy we recommend a hormone and sperm analysis. An early analysis may enable a more successful family planning. Hintergrund: Um zu klären, wie viele Überlebende nach Krebs im Kindesalter unfruchtbar sind und warum, führten wir 2006 eine Umfrage unter ehemaligen Patienten zweier kinderonkologischer Zentren und 2008 eine bundesweite Umfrage durch. 2008/2009 schlossen wir eine Studie „Hormon- und Spermienanalysen nach Chemo- und Strahlentherapie im Kindes- und Jugendalter” an. Patienten und Methoden: Angeschrieben wurden 748 ehemalige kinderonkologische Patienten, die zum Umfragezeitpunkt volljährig waren. Serum- und Spermienproben wurden analysiert. Ergebnisse: Wir erhielten 159 Blutproben (86 Frauen, 73 Männer). 42 Männer nahmen an der Spermienanalyse teil. Das Durchschnittsalter der Teilnehmer war zum Umfragezeitpunkt 25 Jahre. Bei 14/86 Teilnehmerinnen (16%) wurden Anti-Müller-Hormon-Werte (AMH) <0,1 ng/ml bestimmt. Die Follikelreserve scheint hier sehr deutlich eingeschränkt und geht mit dem Verdacht auf Infertilität einher. 21/86 Frauen (24%) hatten AMH-Werte von 0,1–1,0 ng/ml mit dem Verdacht auf eingeschränkte Follikelreserve und damit auf frühzeitiges Ovarialversagen. Bei 23/73 Männern (32%) wurden Inhibin-B-Werte 10 IU/l gefunden, was für eine eingeschränkte Spermiogenese mit erhöhtem Infertilitätsrisiko spricht. 13/42 Spermiogrammbefunden zeigten eine Azoospermie (31%). Diskussion: Die kinderonkologische Therapie führte bei etwa 1/3 der Teilnehmer zu Fertilitätseinschränkungen. In Anbetracht dieser erheblichen Einschränkungen ist es wichtig, Patienten und ihre Familien umfassend aufzuklären, um fertilitätserhaltende Maßnahmen zu ermöglichen. Nach erfolgter Therapie und bestehendem Kinderwunsch empfehlen wir eine Hormon- und Spermienanalyse. Eine frühzeitige Analyse kann eine erfolgreichere Familienplanung ermöglichen.